Latest news with #CollPlantBiotechnologiesLtd
Yahoo
28-03-2025
- Business
- Yahoo
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?
CollPlant Biotechnologies Ltd. () is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The US$30m market-cap company announced a latest loss of US$17m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on CollPlant Biotechnologies' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. CollPlant Biotechnologies is bordering on breakeven, according to some American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$1.1m in 2026. Therefore, the company is expected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 57% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Given this is a high-level overview, we won't go into details of CollPlant Biotechnologies' upcoming projects, though, keep in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period. Check out our latest analysis for CollPlant Biotechnologies Before we wrap up, there's one aspect worth mentioning. CollPlant Biotechnologies currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment. This article is not intended to be a comprehensive analysis on CollPlant Biotechnologies, so if you are interested in understanding the company at a deeper level, take a look at CollPlant Biotechnologies' company page on Simply Wall St. We've also put together a list of important aspects you should look at: Historical Track Record: What has CollPlant Biotechnologies' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CollPlant Biotechnologies' board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Q4 2024 Revenue: $164,000, down from $299,000 in Q4 2023. Full Year 2024 Revenue: $515,000, down from $11 million in 2023. Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023. Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023. Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023. Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023. Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023. Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023. Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023. Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023. Cash and Cash Equivalents (Dec 31, 2024): $11.9 million. Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023. Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023. Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023. Warning! GuruFocus has detected 4 Warning Signs with CLGN. Release Date: March 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate. The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery. CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement. The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm. CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology. CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023. The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023. GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year. Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses. The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships. Q: When can we expect an update from AbbVie on their studies, and are there any anticipated milestone payments in 2025? A: AbbVie is currently reviewing interim results from the first cohort of patients in their dermal filler clinical trials. The next steps will be determined by AbbVie, and we will update the market accordingly. Recently, we received a $2 million payment from AbbVie following a development achievement, but we cannot estimate when the next milestone payment will occur. - Eran Rotem, Deputy CEO and CFO Q: Can you provide details on the market potential and revenue expectations for the VergenixSTR product in Europe and Asia? A: VergenixSTR is intended for treating tendinopathy and has a market potential of 1% to 3% of the population. We are establishing a distribution network in Europe and Asia, and each country requires regulatory approval. We expect to start seeing sales next year, with the product offering a significant advantage over steroid injections. - Yehiel Tal, CEO Q: What is the company's current cash position and burn rate, and how long will it last? A: As of December 31, 2024, we had $11.9 million in cash, not including a recent $2 million payment from AbbVie. Our cost reduction plan does not materially impact main development programs. We expect our cash to support operations through the second quarter of 2026, under conservative assumptions. - Eran Rotem, Deputy CEO and CFO Q: What are the upcoming catalysts for CollPlant's proprietary programs? A: We plan to potentially launch a clinical trial for our photocurable dermal and soft tissue filler within two years. For our regenerative breast implant program, we aim to optimize the implant characteristics and clinical protocol to reach clinical trial readiness. We will also expand the distribution network for VergenixSTR in Europe and Asia and broaden our bioinks product offerings. - Yehiel Tal, CEO Q: How is CollPlant planning to expand sales of its rhCollagen product? A: We plan to expand sales of our rhCollagen to selected customers that align with our business model. This expansion is part of our strategy to support various bioprinting technologies and advance potential partnership discussions. - Yehiel Tal, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
